ArticleCancer medicine2016
Body mass index, weight change, and risk of second primary breast cancer in the WECARE study: influence of estrogen receptor status of the first breast cancer.
Article in Cancer medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Postdiagnosis body fatness, weight change and breast cancer prognosis: Global Cancer Update Program (CUP global) systematic literature review and meta-analysis.International journal of cancer · 2023Pooled it
- Letter to editor on the article by K.‑H. Yoon et al., titled Impact of obesity on breast cancer recurrence by menopausal status and subtype.Breast cancer research and treatment · 2026Article
- Overall and central adiposity and risk of contralateral breast cancer: The California Breast Cancer Survivorship Consortium.International journal of cancer · 2026Article
- Molecule subtypes play important roles for second primary malignancies development based on 324,661 breast cancer survivors.Scientific reports · 2025Article
- Risk factors for second primary breast cancer by laterality, age, and race and ethnicity.Journal of the National Cancer Institute · 2025Article
- Risk factors of developing contralateral breast cancer after first primary breast cancer treatment.Cancer reports (Hoboken, N.J.) · 2024Article
- Racial and Ethnic Disparities in Synchronous and Metachronous Bilateral Breast Cancer.Journal of racial and ethnic health disparities · 2023Article
- The association between physical health-related quality of life, physical functioning, and risk of contralateral breast cancer among older women.Breast cancer (Tokyo, Japan) · 2022Article
- Mammographic texture features associated with contralateral breast cancer in the WECARE Study.NPJ breast cancer · 2021Article
- Risk factors for contralateral breast cancer in postmenopausal breast cancer survivors in the NIH-AARP Diet and Health Study.Cancer causes & control : CCC · 2021Article
- The risk of contralateral breast cancer: a SEER-based analysis.British journal of cancer · 2021Article
- Race, ethnicity and risk of second primary contralateral breast cancer in the United States.International journal of cancer · 2021Article
- A case-control study of the joint effect of reproductive factors and radiation treatment for first breast cancer and risk of contralateral breast cancer in the WECARE study.Breast (Edinburgh, Scotland) · 2020Article
- A Prospective Study of Weight Gain in Women Diagnosed with Early-Stage Invasive Breast Cancer, Ductal CarcinomaJournal of women's health (2002) · 2020Article
- Prediction and clinical utility of a contralateral breast cancer risk model.Breast cancer research : BCR · 2019Article
- Survival and chemotherapy-related risk of second primary malignancy in breast cancer patients: a SEER-based study.International journal of clinical oncology · 2019Article
- CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study.Breast cancer research : BCR · 2018Article
- Body mass index, weight change, and risk of second primary breast cancer in the WECARE study: influence of estrogen receptor status of the first breast cancer.Cancer medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 10 institutions in 3 countries.
Funding
Abstract
Studies examining the relationship between body mass index (BMI) and risk of contralateral breast cancer (CBC) have reported mixed findings. We previously showed that obese postmenopausal women with estrogen receptor (ER)-negative breast cancer have a fivefold higher risk of CBC compared with normal weight women. In the current analysis, we reexamined this relationship in the expanded Women's Environmental Cancer and Radiation Epidemiology (WECARE) Study, focusing on the impact of menopausal status and ER status of the first breast cancer. The WECARE Study is a population-based case-control study of young women with CBC (cases, N = 1386) and with unilateral breast cancer (controls, N = 2045). Rate ratios (RR) and 95% confidence intervals (CI) were calculated to assess the relationship between BMI and risk of CBC stratified by menopausal and ER status. Positive associations with obesity and weight gain were limited to women who became postmenopausal following their first primary breast cancer. Among those with an ER-negative first breast cancer, obesity (vs. normal weight) at first diagnosis was associated with an increased risk of CBC (RR = 1.9, 95% CI: 1.02, 3.4). Also, weight gain of ≥10 kg after first diagnosis was associated with an almost twofold increased risk of CBC (RR = 1.9, 95% CI: 0.99, 3.8). These results suggest that women with an ER-negative first primary cancer who are obese at first primary diagnosis or who experience a large weight gain afterward may benefit from heightened surveillance. Future studies are needed to address the impact of weight loss interventions on risk of CBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.